CD19 and B-cell chronic lymphocytic leukemia: CD19-directed cell therapies have shown promise, but with the exception of recent combination therapy trials where complete response rates can reach 40+% (3–5), only around one-fourth of patients with CLL treated with CD19-directed CAR T-cell therapy will achieve a complete remission (6–10).